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Abstract This clinical review on the treatment of
patients with gastroparesis is a consensus document
developed by the American Motility Society Task
Force on Gastroparesis. It is a multidisciplinary
effort with input from gastroenterologists and other
specialists who are involved in the care of patients
with gastroparesis. To provide practical guidelines
for treatment, this document covers results of
published research studies in the literature and
areas developed by consensus agreement where
clinical research trials remain lacking in the field of
gastroparesis.
Keywords gastroparesis, gastric emptying, prokinetic
agents, antiemetic agents, botulinum toxin.
INTRODUCTION
This consensus document reviews the current treat-
ment options for management of gastroparesis. The
paper was conceived by gastroenterologists with input
from nutrition, diabetology, surgery, pain management
and psychology specialists who are involved in the care
of patients with gastroparesis. To provide practical
therapeutic guidelines, the authors reviewed research
studies published in the literature from 1966 to 2005.
Abstract data presented at meetings of national and
international societies of gastroenterology and gastro-
intestinal (GI) motility where appropriate are discussed
to complement the published findings. Finally, in areas
where clinical trials have not been performed, consen-
sus opinions were formulated by the authors to
facilitate management.
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CLINICAL PRESENTATION
Symptoms
Gastroparesis is a disorder characterized by symptoms
of and evidence for gastric retention in the absence of
mechanical obstruction.1 Gastroparesis typically af-
fects patients, mostly women, and has significant
impact on quality of life.2–4 The true prevalence of
gastroparesis is not known; however, it has been
estimated that up to 4% of the population experiences
symptomatic manifestations of this condition. Diabetes
mellitus is the most common systemic disease associ-
ated with gastroparesis. A similar number of patients
present with gastroparesis of an idiopathic nature.
Postsurgical gastroparesis, often with vagotomy or
damage to the vagus nerve, represents the third most
common aetiology of gastroparesis. The most fre-
quently reported symptoms of gastroparesis include
nausea, vomiting, early satiety and postprandial full-
ness.2 Abdominal discomfort and pain also are noted by
many affected patients and represent challenging symp-
toms to treat.5 Weight loss, malnutrition and dehydra-
tion may be prominent in severe cases. In diabetics,
gastroparesis may adversely affect glycaemic control.
Gastroparesis may also be part of a larger problem of
motor function in generalized dysmotility syndromes
such as chronic intestinal pseudo-obstruction. There is
some overlap between gastroparesis and functional
dyspepsia as both symptoms and gastric emptying test
results may meet definitions for both in a subset of
patients.1,6 As a consequence, some patients with mild
abdominal pain, nausea, vomiting and evidence of
delayed emptying are considered to have functional
dyspepsia by some clinicians and gastroparesis by
others. Patients with marked delay in gastric emptying
should be diagnosed with gastroparesis not functional
dyspepsia. In general, predominant abdominal pain with
lesser degrees of nausea is more consistent with a
diagnosis of functional dyspepsia, whereas predominant
nausea and vomiting with lesser degrees of abdominal
pain is more characteristic of gastroparesis.
Gastric emptying testing
A variety of methods have been advocated for the
measurement of gastric emptying of nutritive and inert
meals. The best accepted technique is scintigraphy
involving ingestion of an egg meal cooked with a
technetium radiolabel. The diagnosis of gastroparesis is
made when a delay in gastric emptying is present and
laboratory studies to rule out metabolic causes of
symptoms and endoscopic and radiographic testing to
exclude luminal blockage have been performed.1 It has
been a common assumption that the GI symptoms can
be attributed to delays in gastric emptying; however,
most investigations have observed only weak correla-
tions between symptom severity and the degree of
gastric stasis. In diabetics, the correlation between
global gastric symptoms and rates of gastric emptying
is poor.7 When individual symptoms have been exam-
ined, only postprandial fullness appears to associated
with delayed emptying of solid food.8 In functional
dyspepsia, symptoms of early satiety, postprandial
fullness, nausea and vomiting are more prevalent in
individuals with delayed gastric emptying than those
with normal emptying.9,10 However, in this condition,
these symptoms exhibit a relatively poor accuracy in
predicting the rate of gastric emptying. More recent
studies confirm an association of delayed gastric
emptying with postprandial symptoms in functional
dyspepsia; however, some symptomatic patients can
exhibit accelerated rather than delayed emptying in the
early postprandial period.11 These observations suggest
that, while delayed gastric emptying of triturated food
may participate in the genesis of symptoms in patients
with gastroparesis, other factors likely to have import-
ant roles as well. This conclusion factors into the
approach to the management of gastroparesis, which
should not only include therapies, which promote




For rational therapy of gastroparesis, it is important to
attempt to understand the pathogenesis of the disorder.
Delays in gastric emptying may result from a variety of
deficits of neuromuscular function. Distinct regional
motor abnormalities of the stomach may have select-
ive effects on global emptying and symptoms. Further-
more, symptomatic manifestations of gastroparesis
require the involvement of the peripheral and the
central nervous systems. Indeed, the act of emesis with
gastroparesis mandates participation of a number of
linked brainstem nuclei. Effective management of
gastroparesis relies on the design of therapies that act
on one or more of these sites.
The different symptoms of gastroparesis may have
their basis from regional abnormalities within the
stomach. Manometric studies have characterized
increases in tonic and phasic motor activity of the
pylorus in subsets of gastroparesis patients.12 This,
along with antral hypomotility, may be the cause of
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delays in gastric emptying in individuals with gastrop-
aresis.13 Alterations in compliance and accommodation
of the proximal stomach may explain symptoms such
as early satiety and postprandial fullness and discom-
fort.14–16 Heightened perception of gastric distention
has been described in diabetic patients with upper GI
symptoms suggesting a possible contribution from
visceral afferent hypersensitivity to symptoms such as
nausea and pain. Further, many patients have associ-
ated dysmotility of the small bowel whose contribution
to the clinical syndrome has not been well-defined.13
Potentially, each of these regional abnormalities repre-
sents a distinct and useful therapeutic target.
Assessment of disease severity
Many therapies of gastroparesis relieve symptoms only
in subsets of gastroparesis patients or are associated
with significant side-effects. Recent investigations
have focused on the quantification of disease severity
both for research purposes and to assist in the delin-
eation of which patients are likely to benefit from the
different modes of treating gastroparesis. A symptom
questionnaire, the Gastroparesis Cardinal Symptom
Index (GCSI), has been developed and validated in
university-based clinical practices for quantifying
symptoms in gastroparesis.17 The GCSI is based on
three subscales (postprandial fullness/early satiety,
nausea/vomiting and bloating) and represents a subset
of the longer Patient Assessment of Upper Gastroin-
testinal Disorders-Symptoms (PAGI-SYM). In addition,
a simple clinical severity grading scale was proposed in
2003 but has yet to validated (Table 1). Future inves-
tigations will determine if the use of such scoring
systems for patient stratification will improve care.
The general principles for treating symptomatic
gastroparesis are to: (i) correct and prevent fluid,
electrolyte and nutritional deficiencies; (ii) reduce
symptoms and (iii) identify and rectify the underlying
cause of gastroparesis, if possible.1 Care of patients
generally relies on dietary modification, medications
that stimulate gastric motor activity and antiemetic
drug therapy. Although in most cases, rigorous inves-
tigations have not assessed therapeutic responses as a
function of symptom severity, a number of basic
recommendations can be made. For mild symptoms
(grade 1), dietary modifications should be tried. When
possible, patients should avoid the use of medications
that delay gastric emptying. If needed, low doses of
antiemetic or prokinetic medications can be taken on
an as needed basis. Diabetic patients should strive for
optimal glycaemic control to minimize effects of
hyperglycaemia on gastric function. For individuals
with compensated gastroparesis (grade 2), treatment
recommendations commonly involve a combination of
antiemetic and prokinetic medications given at regu-
larly scheduled intervals to relieve more chronic
symptoms of nausea, vomiting, fullness and bloating.
These agents frequently have no effect on the pain and
discomfort that may be associated with gastroparesis.
In these patients, measures which are directed to pain
control but which do not exacerbate the other mani-
festations of gastroparesis must be designed. For
patients with severe gastroparesis (grade 3), more
aggressive treatments including hospitalization for
i.v. hydration, insulin administration and i.v. admin-
istration of antiemetic and prokinetic agents are con-
sidered. Chronic care of these individuals may include
enteral or parenteral nutritional support with endo-
scopic and/or surgical intervention.
DIETARY AND NUTRITIONAL
RECOMMENDATIONS
There have been no published controlled trials exam-
ining the effects of dietary interventions on clinical
outcomes in patients with gastroparesis. Nevertheless,
a number of dietary recommendations can be made
based on our understanding of the physiology of gastric
emptying of foods of different physical properties and
different nutrient classes.18 Such dietary recommenda-
tions are likely to be of greatest benefit to those with
mild disease (grade 1), but should also be offered to
patients with more severe gastroparesis (grades 2 and 3)
to complement pharmaceutical and non-pharmaceuti-
cal therapies.
A careful patient history can identify intolerances to
specific foods, such as dairy products or red meats,
which can be addressed during design of a diet
programme for the patient with gastroparesis. The
physical examination should include attention to
Table 1 Proposed classification of gastroparesis severity
Grade 1: Mild gastroparesis
Symptoms relatively easily controlled
Able to maintain weight and nutrition on a regular diet
or minor dietary modifications
Grade 2: Compensated gastroparesis
Moderate symptoms with partial control with
pharmacological agents
Able to maintain nutrition with dietary and lifestyle
adjustments
Rare hospital admissions
Grade 3: Gastroparesis with gastric failure
Refractory symptoms despite medical therapy
Inability to maintain nutrition via oral route
Frequent emergency room visits or hospitalizations
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dentition. Impaired mastication resulting in consump-
tion of poorly chewed food could compound the defect
in antral trituration. Reducing meal size and increasing
the number of meals to 4–6 per day are reasonable
initial recommendations to minimize postprandial
gastric distention. Patients are instructed to chew food
well, to avoid foods that cannot be chewed easily, to
take fluids throughout the course of the meal and to sit
or walk for 1–2 h after meals. A diet low in indigest-
ible, insoluble fibre is advocated as fibre delays gastric
emptying and can contribute to bezoar formation in
those with profound gastric stasis.19 Likewise, fibre
supplements for treatment of constipation should be
discontinued if possible. Fatty foods should be restric-
ted as lipids delay emptying. However, fat-containing
liquids may be tolerated and provide needed calories. A
daily multivitamin/mineral supplement can be taken
if dietary intake is inadequate.
If these measures are ineffective, the patient may be
advised to consume the bulk of their calories as liquid
because gastric emptying of liquids often is preserved
in gastroparesis. To meet the nutritional needs of the
patient, it may be necessary to supplement the diet
with a commercially available liquid nutrient prepar-
ation that is low in fat and fibre. Homogenized solid
meal supplements such as blenderized foods may be
used as a liquid nutrient source. Poor tolerance of a
liquid diet is predictive of a future poor success with
more solid food, even if pureed.
PROKINETIC MEDICATION THERAPY
Prokinetic medications enhance contractility of the GI
tract and promote the movement of luminal contents in
an antegrade direction (Table 2). There has been little in
the way of controlled investigations directly comparing
the different prokinetic medications. A meta-analysis
assessing benefits of four different drugs in 514 patients
in 36 clinical trials reported that the macrolide antibi-
otic erythromycin is the most potent stimulant of
gastric emptying, while erythromycin and the dopam-
ine receptor antagonist domperidone are best at redu-
cing symptoms of gastroparesis.20 However, as for all
meta-analyses, concerns can be raised regarding publi-
cation bias in which negative studies are not reported
and marked differences in study design that can inval-
idate comparisons of the different drugs. Thus, several
factors must be considered when choosing a prokinetic
drug for the patient with gastroparesis including effic-
acy, toxicity, regional availability and cost.
Dopamine receptor antagonists
Dopamine is an inhibitor of motor activity of the
stomach. Two agents, which act as dopamine receptor
antagonists, metoclopramide and domperidone, are
commonly used in patients with gastroparesis. Both
agents act to counteract the inhibitory effects of
endogenous dopamine on gastric emptying. They fur-
ther act as antiemetic agents by virtue of their
blockade of dopamine receptor-mediated pathways in
the brainstem. Metoclopramide also acts as a serotonin
5-HT4-receptor agonist to stimulate cholinergic neural
pathways in the stomach and a weak 5-HT3-receptor
antagonist.
Metoclopramide has been approved for short-term
use (4–12 weeks) since 1979. Several studies have
evaluated the efficacy of metoclopramide for the
treatment of gastroparesis. In one 3 week double-blind
trial, metoclopramide produced greater symptom
improvement and acceleration of gastric emptying
than placebo.21 Similar results were observed in other
placebo-controlled crossover studies; however, individ-
ual improvements in gastric emptying correlated
poorly with reductions in nausea and vomiting empha-
sizing that symptom benefits may not result from the
Table 2 Prokinetic medication classes for treatment of gastroparesis
Class of agent Presently available
Available under
special circumstances Under study
Dopamine D2-receptor antagonists Metoclopramide Domperidone* Itopride
Motilin receptor agonists Erythromycin, clarithromycin,
azithromycin
Mitemcinal
5-HT4-receptor agonists Tegaserod Cisapride Renzapride, mosapride
Muscarinic receptor agonists Bethanechol
Acetylcholinesterase inhibitors Physostigmine, neostigmine
CCK receptor antagonists Loxiglumide, dexloxiglumide
*Via FDA IND and IRB approval.
Under strict compassionate use protocol approved by pharmaceutical company and IRB.
FDA, Food and Drug Administration; IND, investigational new drug; IRB, Institutional Review Board; CCK, cholecystokinin.
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prokinetic actions of the drug and that antiemetic
mechanisms may be important for clinical effic-
acy.22,23 One additional possible mechanism of action
of metoclopramide is to normalize gastric slow wave
dysrhythmias.24
Metoclopramide is generally begun at a oral dose of
5–10 mg 30 min before meals and at bedtime, which
can be increased to 20 mg four times daily if necessary
and if there are no side-effects. For patients who may
not efficiently empty pills from the stomach for
absorption, metoclopramide is available in a liquid
formulation. An orally disintegrating preparation may
soon be available. For individuals with more refractory
nausea and vomiting and unable to retain oral medi-
cations, subcutaneous injections of metoclopramide
have shown symptomatic efficacy in patients.25 Final-
ly, i.v. metoclopramide is often used in inpatient care
of the patient with gastroparesis.
Most of the severe side-effects of metoclopramide
result from its ability to easily cross the blood–brain
barrier. Up to 30% of patients cannot tolerate meto-
clopramide due either to drowsiness and fatigue or to
restlessness and irritability. Acute dystonic reactions
develop in approximately 1% of patients, often within
24–48 h of initiating treatment. Prolonged treatment
infrequently may produce Parkinsonian-like symp-
toms. Tardive dyskinesia, characterized by involuntary
movement of the face, tongue, or extremities, is an
infrequent adverse effect of prolonged use of meto-
clopramide that may not reverse upon discontinuing
the medication. The prevalence of tardive dyskinesia
ranges from 1% to 10% when taking metoclopramide
for at least 3 months.26,27 Doctors should discuss the
risk of tardive dyskinesia with their patients and
document this discussion in their medical record. Some
clinicians have patients sign an informed consent to
document communicating the risks of metoclopra-
mide. Other common side-effects of metoclopramide
relate to its actions to stimulate prolactin secretion
from the pituitary and include breast tenderness,
galactorrhoea and menstrual irregularities.
Domperidone, a peripheral dopamine receptor ant-
agonist, has been studied most extensively in diabetic
gastroparesis. The drug stimulates both liquid- and
solid-phase gastric emptying; however, the symptom
benefits of domperidone do not clearly relate to its
motor stimulatory actions but may instead stem from
its antiemetic properties.28 In a trial of diabetics with
symptoms suggestive of gastroparesis, 260 patients
initially received domperidone at 20 mg four times a
day for 4 weeks.29 Eighty percentage of these individ-
uals responded to therapy, defined as more than 30%
reduction in symptoms. Responders were randomized
to double-blind continuation of domperidone vs with-
drawal on placebo. Those maintained on domperidone
reported significantly greater persistence of symptom
benefit compared with those withdrawn from active
drug regardless of the results of gastric emptying
testing. In a small study of six patients with diabetic
gastroparesis, symptom improvement on domperidone
was associated with resolution of gastric slow wave
dysrhythmias suggestive of a possible gastric antidys-
rhythmic effect of this agent.30
Domperidone is generally started at 10 mg four times
a day. If symptoms persist, the dose is increased to 20–
30 mg four times daily. A trial of 80–120 mg day)1 for
up to 1 month is considered the time needed to assess
its efficacy. Because it does not cross the blood–brain
barrier, domperidone has a more favourable side-effect
profile compared with metoclopramide. Dystonias and
other movement disorders are exceedingly uncommon
with this agent. Domperidone is often used in patients
whom have had side-effects to metoclopramide. Dom-
peridone is especially useful in gastroparetic patients
with Parkinson’s disease in whom it can improve
gastric emptying without blocking the central dopam-
inergic actions of treatment for Parkinson’s disease.31
The anterior pituitary lies outside of the blood–brain
barrier; hyperprolactinaemic effects represent the major
adverse effects of domperidone therapy. An i.v. form of
domperidone was withdrawn in the 1980s due to rare
reports of fatal cardiac dysrhythmias.
In the United States, domperidone is not approved by
the Food and Drug Administration (FDA) and cannot be
obtained by routine prescription or covered by health-
care plans. Traditionally, domperidone has been obtain-
able from other countries, from Internet websites, or
from compounding pharmacies within the USA. These
practices have been discouraged by the FDA. Domperi-
done can be obtained through a FDA investigational
new drug application (IND) with local Institutional
Review Board (IRB) approval. Using this mechanism,
patients sign an informed consent document and pur-
chase domperidone from an FDA-approved pharmacy.
Other dopamine receptor antagonists are in develop-
ment. Itopride, an agent with dopamine antagonist and
acetylcholinesterase inhibitory properties, accelerates
gastric emptying in patients with diabetic gastroparesis
and is used in Asia as a therapy for functional
dyspepsia.32,33 In North America, itopride is currently
in phase III clinical trials.
Motilin receptor agonists
Motilin, an endogenous peptide hormone released by
the duodenal mucosa, elicits antroduodenal contrac-
Volume 18, Number 4, April 2006 Treatment of gastroparesis
 2006 The Authors
Journal compilation  2006 Blackwell Publishing Ltd 267
tions via activation of smooth muscle L-type calcium-
channels after occupation of motilin receptors on
enteric neurones and smooth muscle tissue.34 A num-
ber of macrolide antibiotics act as motilin receptor
agonists to promote upper gut transit, including eryth-
romycin, clarithromycin and azithromycin.35,36 When
given i.v., erythromycin is the most potent stimulant
of gastric emptying among the available prokinetic
drugs.37 The regional actions of erythromycin include
stimulation of cholinergic nerves in the antrum which
elicit co-ordinated phasic contractions and activation
of inhibitory nerves in the pylorus which promote
pyloric relaxation.38–40
A number of controlled and open trials have reported
clinical benefits of erythromycin therapy in patients
with gastroparesis. Symptom improvement has been
noted in 43% of patients treated with oral erythro-
mycin.41 However, the utility of chronic oral erythro-
mycin therapy may be limited by development of
tachyphylaxis as a consequence of motilin receptor
downregulation which can develop within days of
initiating treatment.42 When given chronically, eryth-
romycin is usually started in low doses (125 mg two to
four times daily) in liquid form to facilitate its
absorption. Dosing can be titrated as needed for
clinical effect. Side-effects of erythromycin therapy
are common and include nausea, vomiting and abdom-
inal pain that may occur more prominently at higher
doses. Recently, a review of a large Medicaid cohort
observed approximately a twofold increased risk of
sudden cardiac death in individuals on erythromycin
therapy.43 This risk was further increased by concom-
itant use of cytochrome P-450 (CYP-3A) inhibitors
such as verapamil or diltiazam. Azithromycin does
not have the cardiac risk and has been proposed as
an alternative, although long-term data are not
available.36
A recent focus of pharmaceutical investigation has
been the development of motilin receptor agonists
exhibiting prokinetic capabilities but without antimi-
crobial properties. An early motilin agonist, ABT-229,
actually worsened symptoms in diabetics with nausea
and vomiting compared with placebo and showed no
benefits in functional dyspepsia.44,45 A newer agent,
mitemcinal, exhibits potent prokinetic action in
the stomach and early results in diabetic gastroparesis
show good effects.46 Ghrelin, a neurohumoral trans-
mitter secreted by the stomach, is believed to play
a physiological role as a stimulant of food intake.
Recent preliminary investigations show a prokinetic
action of ghrelin with stimulation of gastric
emptying in patients with diabetic and idiopathic
gastroparesis.47,48
5-HT4-receptor agonists
Cisapride is the best characterized 5-HT4-receptor
agonist with prokinetic properties in the GI tract.
Cisapride activation of 5-HT4-receptors facilitates
release of acetylcholine from myenteric cholinergic
nerves throughout the gut. The functional conse-
quences of this action are to stimulate antral contrac-
tions, improve antroduodenal co-ordination and
accelerate gastric emptying.49,50 Cisapride initially
was approved by the FDA for treatment of nocturnal
heartburn in patients with gastro-oesophageal reflux
disease. Studies demonstrated symptom benefits in
patients with gastroparesis which lasted for at least
1 year.51 As a result, cisapride became a drug of choice
for management of gastroparesis. In prolonged post-
marketing surveillance, a number of cases of sudden
death from cardiac dysrhythmias were attributed to
cisapride use.52 Subsequent investigations implicated a
direct action of cisapride on cardiac potassium-chan-
nels, which promoted QT interval prolongation and
predisposed patients to development of ventricular
dysrhythmias including Torsades de pointes. Patients
with underlying cardiac disease, especially of the
conduction system, and those on medications known
to prolong the QT interval are the main groups at risk.
Because of this adverse effect, cisapride was withdrawn
from the USA market in 2000. Currently, the drug is
available in the United States through a compassionate
use/limited-access programme through Janssen Phar-
maceutica (Titusville, NJ, USA) with strict patient
monitoring.52 Cisapride also can be obtained from
Internet websites and in various geographic sites
worldwide. However, its use is discouraged by the
authors of this consensus paper.
Tegaserod, a 5-HT4-receptor agonist, is approved for
treatment of constipation-predominant irritable bowel
syndrome and chronic constipation. Although its
prokinetic actions appear to be greatest in the small
intestine and proximal colon, tegaserod given at a
dose of 6 mg twice daily accelerates gastric emptying
in healthy volunteers.53,54 In an abstract publication
of 163 patients with gastroparesis, tegaserod was
shown to accelerate solid-phase gastric emptying
which was most pronounced at doses higher than
those commonly used to treat constipation (6 mg
three times daily and 12 mg twice daily).55 The
effect of tegaserod on symptoms was not reported.
Because of this prokinetic effect, tegaserod has been
used on an off-label basis for the treatment of
gastroparesis. Studies are ongoing to determine if the
prokinetic actions of tegaserod produce clinically
meaningful symptom improvements in diabetics with
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gastroparesis. Tegaserod has no effects on the cardiac
QT interval.56
Other 5-HT4-receptor agonists have been developed
and show efficacy in gastroparesis. Mosapride acceler-
ates gastric emptying in healthy volunteers and
patients with diabetic gastroparesis.57,58 Furthermore,
the drug may improve glycaemic control in diabetics
with delayed gastric emptying.58 In contrast to cisa-
pride, mosapride has little effect on potassium-channel
activity and appears to exhibit a significantly lesser
cardiac dysrhythmogenic potential.59 Renzapride is a
combined 5-HT4-receptor agonist and 5-HT3-receptor
antagonist. Future studies are needed to determine if
renzapride exhibits efficacy in gastroparesis.
Other prokinetic medications
Other agents have been proposed as motor stimulatory
treatments in gastroparesis. The cholinergic muscarinic
receptor agonist bethanechol increases phasic antral
motor activity; however, the elicited contractions are
not peristaltic and do not facilitate gastric empty-
ing.60–62 Bethanechol also produces significant side-
effects including flushing, diaphoresis, nausea and
abdominal discomfort. As a consequence, bethanechol
is rarely used alone for treating gastroparesis. Some
clinicians employ the medication in low doses in
combination with other prokinetic agents; however,
this practice has not been subjected to a clinical trial.
Acetylcholinesterase inhibitors, such as physostig-
mine and neostigmine, stimulate gut motor activity
by increasing acetylcholine levels with subsequent
muscarinic receptor activation. As with bethanechol,
anticholinesterase agents do not improve antroduo-
denal co-ordination and have inconsistent effects on
gastric emptying.63 Some H2-receptor antagonists,
such as nizatidine, exhibit anticholinesterase activity
and stimulate gastric emptying but their efficacy in
long-term treatment of gastroparesis is unknown.64,65
The a-adrenoceptor receptor agonist clonidine was
reported to accelerate gastric emptying in a small
study of patients with diabetic gastroparesis, but
delayed gastric emptying in another trial.66,67 Chole-
cystokinin receptor antagonists accelerate gastric
emptying in some studies. The utility of such agents
in gastroparesis remains to be determined.
ANTIEMETIC MEDICATION THERAPY
As stated above, it is likely that a component of the
clinical benefits observed with some of the available
prokinetic drugs, such as metoclopramide and dom-
peridone, stem from antiemetic actions on brainstem
nuclei (Table 3). Use of antiemetic medications with-
out prokinetic potential to reduce nausea and vomiting
associated with gastroparesis is common clinical prac-
tice. However, there is very limited literature on the
use of antiemetic agents in gastroparesis. Indeed, a
careful Medline search revealed only a single case
study reporting on the use of the non-prokinetic
dopamine receptor antagonist thiethylperazine in
gastroparesis.68 Most of the standard antiemetic agents
have no effect on gastric motor function; some may
delay stomach emptying. It is the consensus opinion of
the authors that use of antiemetic medications may be
beneficial in cases in which prokinetic drug therapy is
ineffective or produces unacceptable toxicity. Indeed, it
is possible that some cases of gastroparesis may show
superior responses to antiemetics. In refractory
patients of gastroparesis (grade 3), both prokinetics
and antiemetics are often used in combination to
address control of symptoms. Although pharmacoge-
Table 3 Antiemetic medication classes
Class of agent Examples
Dopamine D2-receptor antagonists
With prokinetic activity Metoclopramide, domperidone






Tricyclic antidepressants Desipramine, nortriptyline, amitriptyline
Muscarinic M1-receptor antagonists Scopolamine, hyoscyamine, clinidium
Histamine H1-receptor antagonists Dimenhydrinate, meclizine, promethazine
Cannabinoids Tetrahydrocannabinol
Benzodiazepines Lorazepam
Neurokinin NK1-receptor antagonists Aprepitant
The H1, D2 and M1 receptor antagonists have overlap. The classification reflects the
predominant activity.
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nomics related to phase I reactions are relevant to the
combination of prokinetics and antiemetics, there is
no evidence to suggests that adding an antiemetic
agent adversely affects the clinical course of patients.
Antiemetic medications reduce vomiting by action
on a diverse range of receptor subtypes in the peripheral
and central nervous systems (Table 3). When consider-
ing antiemetic drug use in gastroparesis, the clinician
should take into account factors such as side-effects,
interactions with other medications, development of
tolerance and cost. The most commonly prescribed
traditional antiemetic drugs are the phenothiazines,
which act as both dopamine and cholinergic receptor
antagonists. These agents include prochlorperazine and
thiethylperazine, which are believed to act primarily in
the area postrema. Cholinergic muscarinic M1-receptor
antagonists are commonly employed for disorders
involving vestibular pathways, including motion sick-
ness. Transdermal scopolamine is occasionally used to
treat nausea and vomiting in gastroparesis,69 although
there is no published data to support this practice.
Muscarinic antagonists such as hyoscyamine and
clidinium delay gastric emptying.70,71 Histamine
H1-receptor antagonists exhibit the greatest benefit in
conditions that activate vestibular pathways, such as
motion sickness and labyrinthitis, and some cases of
postoperative emesis.72,73 Pure H1 antagonists include
dimenhydrinate and meclizine, whereas promethazine
has mixed actions on other receptor subtypes. Many of
these agents have a mild inhibitory effect on gastric
emptying.74 The serotonin 5-HT3-receptor antagonists
have efficacy in chemotherapy-induced emesis, post-
operative emesis and radiation therapy-induced vomit-
ing. An abstract reported that ondansetron produced
small but statistically significant reductions in nausea,
vomiting and abdominal pain in 17 patients with
refractory unexplained nausea and vomiting.75 On-
dansetron has no effect on gastric emptying in healthy
volunteers and patients with gastroparesis,76,77
although one investigation observed inhibition of gas-
tric activity with tropesitron.78 Cannabinoids exhibit
potency equal to or slightly greater than dopamine
receptor antagonist antiemetic drugs in chemotherapy-
induced emesis, and may have additional appetite
stimulatory effects.79 Benzodiazepines are useful in
the management of anticipatory nausea and vomiting
prior to chemotherapy administration, in large part
because of their anxiolytic and tranquilizing effects.
Benzodiazepines do not affect gastric emptying and
may be useful in i.v. form for inpatients with gastro-
paresis by virtue of their sedating actions.80 The most
recently introduced antiemetics are the neurokinin
NK1-receptor antagonists, which are available for
prophylaxis and treatment of chemotherapy-evoked
nausea and vomiting.81,82 The utility of these agents
in reducing symptoms in patients with gastroparesis
must be subjected to controlled investigation.
One group of medications with antiemetic proper-
ties, the tricyclic antidepressant agents, may warrant
special attention as a potential therapy for certain
patients with gastroparesis. Low-dose tricyclic drugs
are commonly prescribed by gastroenterologists for
refractory functional bowel diseases such as irritable
bowel syndrome. In a recent retrospective evaluation,
tricyclic drugs given for a mean of 5 months produced
moderate to complete symptom reductions in the
majority of patients with functional vomiting.83 In a
preliminary abstract on the retrospective analysis of
24 diabetics with nausea and vomiting unresponsive to
prokinetic drugs, 88% experienced symptom reduc-
tions on tricyclic medications at a median dose of
50 mg day)1 and one-third of patients reported symp-
tom remission.84 Nearly one-third of patients had a
pre-existing delay in gastric emptying, suggesting that
tricyclics may be effective in some cases of gastropa-
resis even though this drug class traditionally has been
considered to delay gastric emptying. Future prospect-
ive controlled trials will define the role of this group of
medications in the management of gastroparesis.
Complementary and alternative medicine therapies
often are given for treatment of nausea and vomiting.
Ginger, a traditional Chinese antiemetic agent, exhib-
its weak 5-HT3-receptor antagonist properties and has
gastric slow wave antidysrhythmic effects in hu-
mans.85,86 Acupressure and electrical acustimulation
on the P6 acupuncture point (the Relief Band) have
shown variable success for postoperative emesis,
chemotherapy-induced vomiting and nausea of preg-
nancy.87 One study has reported benefits of acupunc-
ture in 35 gastroparesis patients.88
MEDICATIONS FOR PAIN CONTROL
In some patients with gastroparesis, pain represents a
prominent symptom and can produce significant mor-
bidity and utilization of healthcare resources.2,5 The
pathogenesis of pain in gastroparesis is poorly under-
stood and treatments for this symptom largely are
unsatisfactory. In diabetics with gastroparesis, pain has
been considered to be a consequence of autonomic
neuropathy. However, one small study found that
more severe forms of visceral afferent neuropathy were
associated with fewer rather than more symptoms.89
To date, there have been no studies to specifically
address the effectiveness of any therapy of abdominal
pain in patients with gastroparesis.
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The approach to dealing with pain in these patients
begins with an empathetic understanding by the doctor
with recognition that pain is a valid component of the
gastroparesis symptom complex. The role of pharmac-
otherapy in the management of pain with gastroparesis
is complicated by potential drug toxicities and drug
properties, which can delay emptying and/or worsen
symptoms thereby counteracting the benefits of pro-
kinetic and antiemetic medications. Several medica-
tion classes offer theoretical benefits for reducing pain
in the gastroparesis patient. Non-steroidal anti-inflam-
matory agents ameliorate gastric slow wave dysrhyth-
mias in several healthy human models.90 Furthermore,
oral indomethacin and i.v. ketorolac have been repor-
ted to resolve slow wave abnormalities in diabetics and
patients with dyspeptic symptoms.91,92 However, non-
steroidal agents are potentially ulcerogenic and may
worsen renal function in some diabetics. Thus, their
routine use cannot be advocated by the authors of this
consensus document although selected patients can be
considered for these drugs. In addition to their poten-
tial utility as antiemetics, tricyclic medications in low
doses may reduce pain associated with gastroparesis
much as they do in other forms of neuropathic pain.93
Other antidepressant classes including selective sero-
tonin reuptake inhibitors (SSRIs), selective noradren-
aline reuptake inhibitors and combined serotonin/
noradrenaline reuptake inhibitors (such as the novel
agent, duloxetine, which was recently approved for
diabetic neuropathy) may have benefits as well; how-
ever, there are no data on their actions on visceral
nerve function.94 Among SSRIs, paroxetine may selec-
tively accelerate small intestinal transit.95,96 Other
agents with efficacy in peripheral neuropathic pain
such as gabapentin and topiramate have unknown
actions in patients with pain associated with gastrop-
aresis.97,98 The a-adrenoceptor receptor agonist cloni-
dine exhibits visceral antinociceptive effects, but its
effects on pain with gastroparesis are uncertain.99
Unfortunately many patients with severe pain do not
respond to more conservative therapies and are given
intermittent or chronic therapy with opiate agents for
pain control. Although narcotic agents produce gener-
alized analgesia, their efficacy in gastroparesis is
unproved. Furthermore, opiates exert potent inhibitory
effects on GI transit inhibiting gastric emptying and
colonic transit.100 Finally, chronic narcotic use may
result in tolerance to its analgesic effects, physical
dependence and addiction. Thus, the routine use of
opiate agents for the management of pain with gastro-
paresis is not advocated by the authors. If narcotics are
to be considered, milder agents such as tramadol, an
opioid with less impact on l-opiate receptors, may
produce fewer side-effects.100 Longer acting compounds
such as methadone or continuous release preparations
such as transdermal fentanyl may elicit less constipa-
tion than other narcotics.101,102 A current area of drug
development is the generation of peripheral opioid
receptor antagonists which block peripheral effects of
narcotic drugs but preserve the central analgesic
effects.103,104 However, a study of the novel peripheral
l-opiate receptor antagonist alvimopan observed rever-
sal of the inhibitory effects of codeine on the small
intestine and colon but not the stomach.105
PSYCHOLOGICAL SUPPORT
Unrelenting nausea and vomiting, often with associ-
ated pain, frequently combine to produce significant
psychological consequences. Virtually all studies
examining psychological aspects of gastroparesis and
functional dyspepsia show impaired quality of life and
increased levels of anxiety, depression and somatiza-
tion.2,106,107 Furthermore, one study has reported that
measures of psychological dysfunction correlated bet-
ter with gastropathic symptoms in diabetics than do
measures of neuropathy and gastric emptying.108
Patients with gastroparesis need an empathetic doc-
tor who recognizes the emotional disruptions caused by
their GI illness. Instilling hope, addressing pain and
increasing self-management of their chronic illness are
important. Conceptualizing the psychophysiological
aspects of the disease helps the patient focus on what
he/she can control and decreases viewing the disease as
psychiatric in nature.109 Management of severe gastro-
paresis may be enhanced by the active participation of a
team of providers who communicate together and
collaborate effectively.110 The clinical psychologist
can be an important member of the gastroparesis team
to help the patient develop a game plan for coping with
symptoms. Efforts to facilitate psychosocial support
and rehabilitation, including encouraging education
and the support of family and friends, are import-
ant.109,111 Psychotherapeutic interventions can be help-
ful as adjunctive measures. Simple measures such as
relaxation techniques, cognitive restructuring and dis-
traction help promote a sense of control on the part of
the patient. Other techniques such as hypnosis and
biofeedback may benefit some patients.112
SPECIAL CONSIDERATIONS IN THE
DIABETIC PATIENT
In tertiary care centres, up to 50% of patients with
long-standing (>5 years) type 1 (insulin-dependent) or
type 2 (non-insulin-dependent) diabetes may have
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delayed gastric emptying.113 The prevalence of GI
symptoms in diabetics in the primary care setting
appears to be lower. A population-based survey repor-
ted that 18% of diabetics experience frequent dysmo-
tility type, upper GI symptoms, a rate greater than in
non-diabetics.114 Moreover, this survey observed a
trend to an increase in frequency of symptoms in those
with poor glycaemic control. Conversely in a US
epidemiological study, the prevalence of most GI
symptoms was similar in persons with or without
diabetes.115 The presence of impaired motor function
of the stomach in patients with diabetes does not
always lead to development of gastric symptoms. In
one investigation, only 50% of diabetic patients with
delayed gastric emptying reported typical symptoms of
gastroparesis.116 Additionally, diabetics with normal
gastric emptying may have a symptom constellation
indistinguishable from those with delayed gastric
emptying.117 It is a common clinical observation that
diabetic patients with gastroparesis may also exhibit
erratic postprandial blood sugar values. Indeed, loss of
good glycaemic control in a previously well-regulated
diabetic should raise concern for gastroparesis. Gastric
stasis impairs delivery of nutrients and oral hypoglyc-
aemic medications to the small intestine for absorp-
tion. Postprandial hypoglycaemia or hyperglycaemia
may develop depending on how the delivery of nutri-
ents corresponds with the peak absorption of the
medication.
Hyperglycaemia and gastric emptying
A number of studies have demonstrated a relationship
between blood glucose levels and parameters of gastric
function both in diabetic patients and in healthy
volunteers.118,119 In patients with type 1 diabetes,
acute hyperglycaemia to blood glucose levels of 288–
360 mg dL)1 elicits delays in both liquid and solid
gastric emptying.118 Other investigations in diabetics
have demonstrated hyperglycaemia-evoked impair-
ment of postprandial phasic antral contractions and
induction of tachygastria, providing possible mecha-
nisms for the retarding effects on gastric emptying of
high glucose levels.120 Conversely in some type 2
diabetics, liquid-phase gastric emptying may be accel-
erated during hyperglycaemia.121 Investigations in
healthy volunteers observe that acute increases in
blood glucose can abolish phasic antral motor activity,
stimulate pyloric contractions, evoke tachygastria and
enhance fundic compliance, indicating that the degree
of glycaemic control itself can influence gastric func-
tion independently of the presence of underlying
neuropathy.122,123 The relation of the actions of hyper-
glycaemia on gastric function to its impact on symp-
toms is less clear. However, one study has observed a
significant correlation between the degree of hypergly-
caemia and the severity of postprandial fullness in
diabetic patients.124 All studies to date have examined
the functional consequences of acute elevations in
blood glucose. The impact of chronic, long-term
hyperglycaemia on gastric dysfunction in persons with
diabetes is less clear; there are no long-term controlled
studies confirming the importance of good glycaemic
control in reducing symptoms in diabetic gastroparesis.
However, observations from physiological studies sug-
gest that high blood glucose levels can adversely affect
responses to therapy. In both type 1 diabetic patients
and healthy volunteers, induction of acute hypergly-
caemia markedly attenuates the motor stimulatory
effects of the prokinetic drug erythromycin on the
stomach.125,126
Glycaemic control in diabetic gastroparesis
Because of the consistent observations from physiolo-
gical studies that high serum glucose levels adversely
affect gastric function, it is the consensus opinion of
the authors that intensification of therapies to correct
hyperglycaemia may facilitate the actions of and
increase the benefits of other treatments in managing
the patient with diabetic gastroparesis. Measures that
are likely to be effective include more aggressive
glucose monitoring with frequent dosing of short-
acting insulin preparations to prevent profound post-
prandial hyperglycaemia. Prevention of wide fluctua-
tions in serum glucose levels may be more important
than maintenance of a given steady-state blood sugar
value from a gastric emptying perspective.127 To this
end, monitoring 2-h postprandial blood glucose levels
may be useful. Conversely, there is little convincing
evidence to suggests that prokinetic treatment of
delayed gastric emptying can reliably improve glycae-
mic control.128
Glucose control in the type 2 diabetic patient with
gastroparesis can represent a significant challenge. In
many type 2 diabetics, oral hypoglycaemic medica-
tions often are ineffective and can contribute to swings
in blood glucose levels because of the temporal
mismatch between nutrient absorption and medica-
tion. The addition of basal insulin therapy to oral
therapy may be valuable in achieving glycaemic
control in the type 2 diabetic patient. Furthermore,
use of a long-acting insulin preparation with a 24 h
profile that mimics normal pancreatic basal secretion
may improve overall regulation of blood glucose levels.
Newer insulin analogues such as insulin glargine limit
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the number and severity of isolated insulin peaks and
are associated with fewer hypoglycaemic episodes.
Addition of basal insulin glargine or neutral protamine
Hagedorn (NPH) to target a mean fasting plasma
glucose concentration of £100 mg dL)1 facilitates
attainment of glycosylated haemoglobin (HbA1c) val-
ues of <7% in patients who were inadequately
controlled with oral hypoglycaemic agents.129 Patients
on insulin glargine are more likely to reach this goal
without nocturnal hypoglycaemia compared with
those on NPH insulin.
Patients with type 1 diabetes are especially prone to
wide variations in blood glucose levels. The use of a
premixed formulation with both short- and long-
acting insulin requires relatively strict adherence to
meal timing and composition, and assumes that
nutrients will be available within a given time frame
to avoid hypoglycaemia. Because of these restrictions,
premixed insulin may be a poor choice for individuals
with delayed or unpredictable gastric emptying. For
many type 1 diabetic patients, a long-acting prepar-
ation such as insulin glargine may be administered
twice daily with preprandial injections of regular
insulin formulas. However, in those with gastropa-
resis, postprandial hypoglycaemic episodes can occur
when the glucose-lowering effects of preprandial
short-acting insulin precede delivery of nutrients into
the small intestine for digestion and absorption. As a
consequence, some persons with delayed emptying
may need regular insulin dosing during or even after
meal ingestion. Postprandial administration also al-
lows the patient to reduce the insulin dose if vomiting
prevented consumption of the entire meal. Some
patients benefit from use of improved insulin pumps
which can be set to provide a constant basal insulin
infusion 24 h a day. These individuals then adminis-
ter bolus regular insulin injections prior to, during, or
after meals. In selected cases, jejunostomy feedings
may minimize extreme glycaemic fluctuations. Addi-
tional insulin may be needed for those receiving
nocturnal enteral nutrition to correct for the




Patients with chronic symptoms of gastroparesis may
develop dehydration, electrolyte abnormalities and/or
extreme malnutrition. Such individuals warrant care-
ful nutritional assessment and consideration to initiate
supplemental enteral nutrition, or as a last resort,
parenteral nutrition.
Nutritional assessment
Determining the degree of nutritional compromise
involves assessment of symptoms, diet history, body-
weight (bw) and disease course. The conventional
nutritional laboratory assessments of serum albumin
and prealbumin levels are affected by a variety of
factors in gastroparesis and may not be reliable meas-
ures of nutritional status. Unintentional weight loss
over time is probably the most important, non-invasive
parameter for assessing the degree of malnutrition. A
10% loss of weight over 6 months is consistent with
current definitions of significant malnutrition.130 One
should compare the patient’s current actual weight to
his or her usual bw as opposed to the ideal bw, which
can result in overestimation or underestimation of true
weight loss. The subset of diabetic patients with
chronic renal failure requiring haemodialysis requires
careful scrutiny as progressive falls in weight may
reflect either development of gastroparesis or excessive
fluid withdrawal during dialysis. Essential nutrient and
mineral deficiencies, particularly those resulting in
anaemia and metabolic bone disease, require ongoing
monitoring and supplementation if needed. Laboratory
studies should include: (i) electrolytes including mag-
nesium, as hypokalaemia and hypomagnesaemia can
exacerbate delay in gastric emptying; (ii) serum glucose
and HbA1c in diabetic patients; (iii) iron and ferritin
levels particularly for partial gastrectomy settings; (iv)
vitamin B12 and (v) 25-OH vitamin D especially in
those with long-standing gastroparesis or gastroparesis
occurring after partial gastrectomy.
Enteral nutrition
Initiation of enteral feedings is indicated if oral nutri-
tion fails to meet the caloric and fluid needs of the
patient with gastroparesis. Enteral nutrition is prefer-
able to total parenteral nutrition (TPN) in most
individuals, because of issues related to infectious
complications, thrombosis, i.v. access problems, hepa-
tobiliary consequences, administration and cost. Fur-
thermore, TPN rarely is necessary in the patient with
gastroparesis unless there is profound dysmotility also
involving the small intestine as in chronic intestinal
pseudo-obstruction. However, some severely malnour-
ished gastroparetic patients may benefit from a brief
course of TPN to provide supplemental caloric support
and to gain glycaemic control. For these individuals,
30–40 units of regular insulin may need to be added to
each litre of TPN, depending on the patient’s prior
insulin requirements and TPN contents (1 unit regular
insulin per 5 g carbohydrate or 15 g protein).
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Criteria for initiation of enteral nutrition have been
proposed which relate to symptom severity, nutritional
consequences of disease and complications of gastrop-
aresis (Table 4).131 The recommendation to place
enteral access may not initially be accepted by the
patient. Management goals such as desired weight,
reductions in hospitalizations and improved glycaemic
control should be discussed with the patient, such that
the decision to begin enteral feedings is made ration-
ally. Several options for enteral access and feeding are
available (Table 5). There are no data favouring one
approach over another and the choice of access is often
determined by the expertise of the individual centre.
However, infusion of liquid meals into the stomach via
a nasogastric tube or gastrostomy is not advocated
because of the likelihood of symptom exacerbation and
the risk of pulmonary aspiration resulting from the
impairment of gastric emptying. Short-term nasojejun-
al feeding is often used to help determine if the patient
will tolerate chronic small bowel feedings through a
permanent enteral access. Jejunostomies are most
commonly placed by laparotomy or laparoscopy. Direct
percutaneous endoscopic jejunostomy placement is
performed in some centres. Jejunostomy extension
tubes can be passed through pre-existing gastrostomies
for delivery of enteral feedings in patients who are not
candidates for direct jejunostomy access or in whom
such access is not desired for other reasons. In some
individuals, a button device may improve quality of life
and personal appearance. Enteral feedings are usually
initiated 24 h after jejunostomy tube placement. Stand-
ard polymeric formulas with caloric density of 1.0–
1.5 cal mL)1 (e.g. Jevity 1.5, Nutren 1.5 unflavoured,
Promote, or Isosource HN) are begun at low infusion
rates of 25–50 mL h)1 and advanced by 10–25 mL h)1
Table 4 Criteria for initiation of enteral nutrition supple-
mentation
Severe weight loss, e.g. unintentional weight loss >5–10%
of usual bodyweight over 3–6 months
Repeated hospitalizations for refractory gastroparesis
requiring i.v. hydration and/or i.v. medication
Inability to meet weight goals set by doctor, dietician
and patient
Patient would benefit from gastric decompression
Patient would benefit from a way to absorb medications
everyday to gain therapeutic levels when vomiting
prevents this
Patient has maintained usual bodyweight, but experiences
significant clinical manifestations
Diabetic ketoacidosis
Cyclic nausea and vomiting
Overall poor quality of life due to gastroparesis symptoms
Used with permission from the University of Virginia Health
System Nutrition Support Traineeship Syllabus (87).
Table 5 Forms of enteral access for nutrition supplementation
Type of access Usefulness Disadvantages
Nasogastric tube Gastric decompression in acute
management
Not meant for long-term use
Large tube size often causes is comfort
Is a poor choice for feeding due to
delayed gastric emptying
Significant gastro-oesophageal reflux can occur
Nasoduodenal/
nasojejunal tube
Used to give trial feedings to determine
if jejunal feedings are tolerated
May be acceptable if there are no other options
Not for long-term use
Vomiting may expel the tube into the stomach
Gastrostomy tubes May be used for venting of secretions to decrease
vomiting and fullness
Poor choice for feeding due to delayed
gastric emptying
May prevent proper electrode placement
for gastric electrical stimulation
PEG-J or Jet-PEG Allows the patient to vent gastric secretions to
decrease/prevent persistent emesis
Provides jejunal feedings
New PEG-Js have distal feeding ports to reduce
duodenogastric reflux
Migration of the J-tube extension into stomach
Pyloric obstruction from J-tube
May prevent proper electrode placement




Stable access for reliable jejunal nutrient delivery
Avoids gastric penetration which would interfere





Two sites – one for venting and one for
enteral nutrition
Increased risk of leakage, infection
Cosmetic issues
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every 4–12 h until the desired daily caloric intake is
achieved. Liquid formulations of medications can be
given though the jejunostomy followed by low volume
water flushes.131 Individuals should avoid oral intake
during the initial 48–72 h after starting enteral infu-
sions to facilitate determination of patient tolerance of
tube feedings. When first administering enteral nutri-
tion, jejunal feedings should be delivered continuously
24 h a day. Over time, this can be converted to
nocturnal infusions to free up the daytime hours for
optional oral intake and to participate in normal daily
activities. High calorie formulas (1.5–2.0 cal mL)1) can
reduce volumes and times of infusion; however, sup-
plemental hydration may be needed. In those with
considerable weight loss, enteral feedings should be
initiated more slowly to avoid refeeding problems such
as respiratory failure and congestive heart failure.132
Prevention of complications from jejunostomy tubes
include regular flushing after use and routine skin care.
Some centres advocate tube replacements every 3–
6 months to avoid problems such as tube decomposi-
tion and skin infection whereas other institutions
recommend intervention only when adverse issues
arise.
ENDOSCOPIC THERAPY
Some patients with documented gastroparesis exhibit
prolonged periods of increased phasic and tonic motor
activity of the pylorus.12 This phenomenon, termed
pylorospasm, has been postulated to contribute to the
delay in gastric emptying by producing a functional
gastric outlet obstruction.12 In theory, use of a therapy
to reduce pylorospasm might have beneficial actions in
gastroparesis. Botulinum toxin binds to presynaptic
acetylcholine terminals and produces blockade at the
level of the neuromuscular junction thereby preventing
cholinergic transmission and promoting muscle relax-
ation. Endoscopic injection of botulinum toxin into the
pylorus has been shown to reduce fasting and post-
prandial phasic and tonic pyloric contractions in
patients with gastroparesis.133,134 In several small
open-label series, acceleration of gastric emptying and
modest reductions in symptoms have been observed 1–
3 months after pyloric injection of botulinum tox-
in.134–138 Doses have ranged from 80 to 200 units
delivered in circumferential fashion at 4–5 sites into
the pylorus.
More recent retrospective analyses of larger numbers
of patients have provided additional information on the
utility of pyloric botulinum toxin injection.139,140 In
one study of 63 patients in clinical practice, the
response rate was 43% – lower than many of the
initial enthusiastic reports – and the average duration
of response was 5 months.139 In an abstract report of 78
patients, percentages of patients experiencing symp-
tom reductions after pyloric injection of botulinum
toxin were similar in patients with diabetic (55%),
idiopathic (51%) and postsurgical gastroparesis
(44%).140 Prior response to botulinum injection predic-
ted a favourable response to subsequent injection.
Higher doses of botulinum toxin (150–200 units) were
more likely to produce reductions in nausea and
vomiting compared with doses £100 units.
Results of these uncontrolled trials have served as
the impetus for the conduct of placebo-controlled trials
of pyloric injection of botulinum toxin in gastroparesis.
Preliminary results of one investigation reported an
increase of gastric emptying without symptom
improvement.141 However, this preliminary report of
12 patients was underpowered to detect an effect of the
drug. Until appropriate studies are performed, the
authors feel it is appropriate to consider pyloric
injection of botulinum toxin when other accepted
medication therapies have failed or produce unaccept-
able side-effects. To date, few adverse effects have been
reported with botulinum toxin injections thus the
major limiting factors relate to issues of insurance
coverage and the inconvenience of undergoing endo-
scopy.
The therapeutic endoscopist also may offer other
treatment options to individuals with refractory gastr-
oparesis. Endoscopic placement of a venting gastrosto-
my may allow the patient with severe postprandial
fullness or discomfort to release gas and fluid inter-
mittently to reduce symptoms.142,143 In theory, dila-
tion of the pylorus may produce similar benefits as
pyloric injection of botulinum toxin; however, no
studies have been performed to test this method.
GASTRIC ELECTRICAL STIMULATION
Development of practical gastric electrical stimulation
techniques for the treatment of gastroparesis have
been a focus of research over the past decade. Studies
using a gastric pacemaker that delivered high energy
depolarizing stimuli to the stomach just above the
physiological slow wave frequency (3.3 cpm) showed
promise in promoting gastric emptying and reducing
symptoms of gastroparesis.144 However, this system
proved unwieldy because of the large external current
source required to drive the stomach through pacing
electrodes that penetrated the abdominal wall and
sewn to the gastric serosa. In 2000, the FDA-granted
humanitarian device exemption approval for the
Enterra gastric electrical stimulator (Medtronic, Inc.;
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Shoreview, MN, USA) for patients with refractory
diabetic or idiopathic gastroparesis. This system con-
sists of a pair of electrodes sutured to the muscular
layer of the anterior wall of the stomach, which are
connected to a pulse generator implanted in a subcu-
taneous pocket in the abdominal wall. The pulse
generator delivers low energy 0.1 s trains of pulses at a
frequency of 12 cycles per minute. Within each pulse
train, individual pulses oscillate at a frequency of 14
cycles per second.
Clinical outcomes
Two multicentre trials have been conducted to evalu-
ate the efficacy of the gastric electrical stimulator in
patients with diabetic and idiopathic gastroparesis. In
an open-label study, 35 of 38 patients (mostly with
idiopathic gastroparesis) experienced >80% reductions
in nausea and vomiting which persisted for the
duration of the observation period (3–15 months) asso-
ciated with significant weight gain.145 Although many
individuals were able to discontinue enteral or paren-
teral nutrition, one quarter of patients needed to
undergo additional surgeries including subtotal gas-
trectomy for symptom control and device removal for
complications. The second multicentre investigation
represents the only sham-stimulation controlled study
to date.146 In this trial, 33 gastroparesis patients
(16 idiopathic, 17 diabetic) were randomized to sham
vs active stimulation for 1 month each in double-blind,
crossover fashion followed by an open-label stimula-
tion period to 12 months. During the blinded phase,
vomiting frequencies were 14% lower when the device
was ON compared with times when the device was
deactivated – a difference reported to be statistically
significant. Furthermore, patients preferred the ON
period over the OFF period by a threefold margin.
However, the benefits of treatment were predomin-
antly, if not exclusively, experienced by the diabetic
group. During the open phase of the study, electrical
stimulation produced a 76% reduction in vomiting at
12 months. Approximately 15% of patients required
device explant or revision because of complications. In
other open-label, single centre studies, electrical sti-
mulation has been reported to improve nutritional
status, limit the need for prokinetic and antiemetic
medications, reduce the need for supplemental nutri-
tion, decrease health-related costs and improve HbA1c
values in diabetics.110,147–149 In an abstract with long-
term patient follow-up, investigators have observed
26% and 44% reductions in nausea and vomiting,
respectively, persisting for up to 10 years after device
implantation.150 Most recently, the gastric electrical
stimulator has shown efficacy in reducing symptoms
in postsurgical gastroparesis – an unapproved indica-
tion.151,152 The most common complication of this
form of therapy is infection of the subcutaneous
stimulator pocket, which occurs in 5–10% of patients
and nearly always requires surgical removal of the
device. Other complications include wire breakage,
electrode dislodgement or penetration of the stomach,
and intestinal obstruction. Patients should not undergo
magnetic resonance imaging and should avoid certain
metal detecting security devices after stimulator
implantation.
While the results of these investigations are encour-
aging, the clinical benefits of gastric electric stimula-
tion have not been unequivocally demonstrated or the
site of action. A larger, longer duration, sham-stimu-
lation controlled, multicentre trial of gastric electrical
stimulation is ongoing in patients with gastroparesis.
Optimal pulse parameters need to be defined and
predictors of clinical improvement must be character-
ized. Endoscopic placement may offer a much more
attractive lead placement method. A recently reported
method of temporary gastric electrical stimulation via
endoscopically placed electrodes offers a potential
means to preoperatively predict potential response to
surgery.153
Mode of action
The mechanism(s) underlying the clinical benefits of
the gastric electrical stimulator are not fully under-
stood. Most investigations observed only minimal
acceleration of gastric emptying.145,146,148,149 Those
studies reporting acceleration of emptying are com-
posed largely of patients with idiopathic gastroparesis,
a condition which can show progressive spontaneous
improvement. Furthermore, this device does not
entrain slow waves or reverse underlying slow wave
dysrhythmias.154 Recent reports indicate that electrical
stimulation can modulate gastric biomechanical prop-
erties, enhance postprandial proximal gastric accom-
modation and reduce sensitivity to gastric
distension.155,156 An investigation employing cerebral
imaging methods suggests that gastric electrical sti-
mulation has inhibitory actions on afferent pathways
projecting to different regions in the brain.157 Others
have suggested that the benefits of the device may
stem from action on vagal pathways.147,154 However, if
the findings from case series reporting responses in
patients with postvagotomy gastroparesis are repro-
duced, mediation by vagal pathways cannot represent
the sole mechanism of action of gastric electrical
stimulation.152
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Practical considerations
Because of the restrictions imposed by its humanitar-
ian device status, the Enterra gastric electrical stimu-
lator cannot be implanted at any given institution
until its use has been approved by the local IRB.
Although patients with refractory symptoms have
embraced the availability of this device, this special
status has been used by some third party insurance
carriers to deny coverage. Candidates for implantation
of the gastric electrical stimulator include patients
with chronic diabetic or idiopathic gastroparesis with
relentless nausea and vomiting who are not responding
to appropriate diet and medication therapy. There is a
special need in diabetics being considered for renal
and/or pancreas transplantation where it is important
that the immunosuppressive agents will be absorbed.
Conversely, individuals without nausea and vomiting
but with other manifestations of gastroparesis (full-
ness, early satiety, anorexia, pain) have not been
shown to predictably respond to gastric stimulation.
Patients being considered for enteral or parenteral
nutritional support may be given particular considera-
tion for this treatment option. However, one group has
reported in an abstract that aggressive medical therapy
with combination drug therapy (antiemetics and pro-
kinetics in adequate doses) and pyloric injections
of botulinum toxin produces adequate symptom
responses that avoid the need for surgery in up to
two-thirds of patients referred for consideration of
gastric electrical stimulation.158 Contraindications
may include generalized dysmotility syndromes also
involving the small bowel including chronic intestinal
pseudo-obstruction and collagen vascular diseases
such as scleroderma and prior gastric resections.
Although chronic narcotic analgesic use may reduce
the symptomatic benefits of gastric electrical stimula-
tion, the need for opiates should be evaluated on an
individual basis and does not necessarily represent an
exclusion criterion.159 Insertion of a jejunostomy tube
during implantation of the gastric electrical stimulator
should be considered in patients who may have
difficulty meeting their nutritional and hydration
needs.
OTHER SURGICAL OPTIONS
In selected instances, other surgical procedures may be
considered for control of refractory symptoms in
patients with gastroparesis.143 The range of surgical
options includes drainage procedures such as pyloro-
myotomy or pyloroplasty and partial or total gastric
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decrease symptoms. Most published studies are uncon-
trolled and report disappointing responses to operative
resection.143 Of seven patients who underwent partial
(subtotal) gastrectomy with Roux-en-Y gastrojejunos-
tomy, six reported reduced vomiting.160 However,
three individuals developed renal failure and two died
within 5 months of surgery. More impressive results
have been observed in some studies in which total
(completion) gastric resection was performed for post-
surgical gastroparesis.161–163 Results from these uncon-
trolled, retrospective case series observed symptom
reductions in approximately two-thirds of patients
after this drastic surgical option. However, a more
recent study of completion gastrectomy for severe
postsurgical gastric stasis reported successful out-
comes in only 43% of patients.164 In diabetic patients,
pancreatic transplantation has been shown to halt
progression or even partly reverse peripheral polyneur-
opathy.165 However, no consistent benefits of pancreas
transplantation on symptoms or gastric emptying have
been reported in patients with diabetic gastro-
paresis.166,167
CONCLUSIONS
The treatment of gastroparesis includes dietary mod-
ifications, prokinetic and antiemetic medications,
measures to control pain and address psychological
issues, and endoscopic or surgical options in selected
instances. Table 6 lists the consensus opinions of the
authors of this document regarding the organized
approach to treating this challenging condition. The
different therapeutic modalities may be offered alone
or in different combinations as dictated by the needs of
the individual patient. Goals of therapy include relief
of symptoms, normalization of nutrition and hydration
status, improvement of glycaemic control in diabetics,
and improvement of gastric emptying when appropri-
ate. Effective management of the patient with gastrop-
aresis may mandate involvement of a team of
specialists including the primary doctor, gastroenter-
ologist, endocrinologist, dietician, psychologist, inter-
ventional radiologist and surgeon.
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